

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name ☒ Organization/Lobbying Firm ☐ Self Employed Individual

PATTON BOGGS LLP

2. Address ☐ Check if different than previously reported

Address1 **2550 M STREET, NW**

Address2

City **WASHINGTON**

State **DC**

Zip Code **20037**

Country **USA**

3. Principal place of business (if different than line 2)

City

State

Zip Code

Country

4a. Contact Name

b. Telephone Number

c. E-mail

James B. Christian

☐ International Number

(202) 457-6484

LDAdmins@pattonboggs.com

5. Senate ID#

30906-393

7. Client Name

☐ Self

☐ Check if client is a state or local government or instrumentality

Bristol-Myers Squibb

6. House ID#

319170017

TYPE OF REPORT

8. Year **2009**

Q1 (1/1 - 3/31) ☐

Q2 (4/1 - 6/30) ☒

Q3 (7/1-9/30) ☐

Q4 (10/1 - 12/31) ☐

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐

Termination Date

11. No Lobbying Issue Activity ☐

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

12. Lobbying

INCOME relating to lobbying activities for this reporting period was:

Less than \$5,000 ☐

\$5,000 or more ☒ \$ **80,000.00**

Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSE relating to lobbying activities for this reporting period were:

Less than \$5,000 ☐

\$5,000 or more ☐ \$

14. REPORTING

Check box to indicate expense accounting method. See instructions for description of options.

☐ **Method A.** Reporting amounts using LDA definitions only

☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

Signature

Filed Electronically

Date

07/15/2009

Printed Name and Title James B. Christian, Partner

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code

MMM

MEDICARE/MEDICAID

(one per page)

16. Specific lobbying issues

Medicare Prescription Drug Savings and Choice Act (S. 333/H.R. 684); Medicaid Prescription Drug Rebate Equalization Act of 2009 (HR 904); Drug Rebate Equalization Act of 2009 (S 547)
Voluntary State Discount Prescription Drug Plan Act of 2009 (HR 1725)

17. House(s) of Congress and Federal agencies

☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Thomas	Boggs			<input type="checkbox"/>
John	Jonas			<input type="checkbox"/>
Martha	Kendrick			<input type="checkbox"/>
Todd	Tuten			<input type="checkbox"/>
Karen	Thiel			<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Printed Name and Title

James B. Christian, Partner

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code

HCR

HEALTH ISSUES

(one per page)

16. Specific lobbying issues

American Recovery and Reinvestment Act (PL 111-5); Promoting Innovation and Access to Life-Saving Medicine Act (HR 1427/S 726); Pathway for Biosimilars Act (HR 1548); Patient-Centered Outcomes Research Act of 2009 (S1213); Comparative Effectiveness Research Act of 2009 (HR 2502); Doctor-Patient Relationship and Research Protection Act (HR 2824); Protecting Consumer Access to Generic Drugs Act of 2009 (HR 1706); Food and Drug Administration Globalization Act of 2009 (HR 759); Drug and Device Accountability Act of 2009 (S 882)
Pharmaceutical Market Access and Drug Safety Act of 2009 (HR 1298/S 1232)

17. House(s) of Congress and Federal agencies

☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Thomas	Boggs			<input type="checkbox"/>
John	Jonas			<input type="checkbox"/>
Martha	Kendrick			<input type="checkbox"/>
Todd	Tuten			<input type="checkbox"/>
Karen	Thiel			<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>
				<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Printed Name and Title

James B. Christian, Partner

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address

CityStateZip Code - Country

21. Client new principal place of business (if different than line 20)

CityStateZip Code - Country

22. New General description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

1	First NameLast NameSuffix	3	First NameLast NameSuffix
2		4	

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Address	Principal Place of Business (city and state or country)
	Street Address CityState/Province Zip Country	City StateCountry City StateCountry

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

123

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address CityState/Province Country	City StateCountry		%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

135
246